Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response

Digestive Diseases and Sciences

Volumn 58, Issue 2, 2013, Pages 556-561

  Kee, Kwong Ming ^a   Wang, Jing Houng ^a   Hung, Chao Hung ^a   Chen, Chien Hung ^a   Lee, Chuan Mo ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Antiviral therapy; Hepatitis C virus; Platelet count; Sustained virological response; Thrombocytopenia

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON PLUS RIBAVIRIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; RECOMBINANT PROTEIN;

ADULT; ARTICLE; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; CLINICAL TRIAL; DRUG COMBINATION; LIVER CIRRHOSIS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; RECOMBINANT PROTEINS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876319936     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2380-4     Document Type: Article

References (25)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374. doi: 10.1002/hep.22759.
2. Wang JH, Changchien CS, Hung CH, et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010;25:964-969. doi: 10.1111/j.1440-1746.2009.06194.x.
3. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985-994.
4. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-587. doi: 10.1002/hep.21492.
5. Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-414. doi: 10.1111/j.1365-2893.2005.00707.x.
6. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther. 2007;25:1029-1037. doi: 10.1111/j.1365-2036. 2007.03297.x.
7. Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat. 2011;18:1-7. doi: 10.1111/j.1365-2893.2010.01366.x.
8. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000-1007. doi: 10.1016/j.jhep.2008. 03.009.
9. Coverdale SA, Samarasinghe DA, Lin R, et al. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. Am J Gastroenterol. 2003;98:1384-1390. doi: 10.1111/j.1572-0241. 2003.07468.x.
10. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest. 1966;45:645-657. doi: 10.1172/JCI105380.
11. Dai CY, Ho CK, Huang JF, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B and C endemic area in Taiwan. J Hepatol. 2010;52:160-166. doi: 10.1016/j.jhep.2009.11.017.
12. Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol. 1995;50:173-178.
13. Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol. 2002;37:572-577.
14. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212-2222. doi: 10.1002/cncr.22242.
15. Lu SN, Wang JH, Chen PF, et al. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev. 2008;17:1813-1821. doi: 10.1158/1055-9965.EPI-07- 2746.
16. Taniguchi H, Iwasaki Y, Fujiwara A, et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol. 2006;21:281-287. doi: 10.1111/j.1440-1746.2006.04201.x.
17. Moriyama M, Matsumura H, Aoki H, et al. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology. 2003;46:296-307. doi: 10.1159/00007320973209.
18. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-844. doi: 10.1002/hep.23744.
19. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729-738. doi: 10.1002/hep.22694.
20. Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240-8, 1248.e1-2. doi: 10.1053/j.gastro.2011.06.036.
21. Kee KM, Wang JH, Hung CH, et al. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol. 2012;27:1106-1111. doi: 10.1111/j.1440-1746.2011.06946.x.
22. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Social Methods Res. 2001;29:374-393.
23. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526. doi: 10.1053/jhep.2003.50346.
24. Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut. 2005;54:1014-1020. doi: 10.1136/gut.2004. 057893.
25. Madhotra R, Mulcahy HE, Willner I, Reuben A. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol. 2002;34:81-85.